Pages that link to "Q33376803"
Jump to navigation
Jump to search
The following pages link to Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists (Q33376803):
Displaying 50 items.
- Drug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating Aspirin (Q22306342) (← links)
- A review of picotamide in the reduction of cardiovascular events in diabetic patients (Q24681255) (← links)
- Benefit-Risk Assessment of Fish Oil in Preventing Cardiovascular Disease (Q26740486) (← links)
- Platelet signaling (Q26824744) (← links)
- Acetylsalicylic acid reduces perfusion deficit in ischemic injured brain in rats (Q28165474) (← links)
- Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease (Q28165894) (← links)
- Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist (Q28167658) (← links)
- The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding (Q28177082) (← links)
- Aspirin induces erythrocyte nitric oxide synthase activity in vivo (Q28191737) (← links)
- Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance (Q28191924) (← links)
- Gathering intelligence on antiplatelet drugs: the view from 30 000 feet. When combined with other information overviews lead to conviction (Q28192082) (← links)
- The stable analog carbocyclic TXA2 but not platelet-released TXA2 induces osteoclast-like cell formation (Q28195335) (← links)
- Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases (Q28196501) (← links)
- Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis (Q28214002) (← links)
- Mechanism of action of novel NO-releasing furoxan derivatives of aspirin in human platelets (Q28218042) (← links)
- Aspirin delimits platelet life span by proteasomal inhibition (Q28542013) (← links)
- Thromboxane and the thromboxane receptor in cardiovascular disease (Q33899567) (← links)
- Human prostacyclin receptor (Q34164660) (← links)
- COX-2 and beyond: Approaches to prostaglandin inhibition in human disease (Q34282832) (← links)
- Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. (Q34433987) (← links)
- Selection of anticoagulants or antiplatelet-aggregating agents for prevention of stroke (Q34566663) (← links)
- The Endothelium and Its Role in Regulating Vascular Tone (Q34582309) (← links)
- Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice (Q34730034) (← links)
- Total artificial hearts: bridge to transplantation (Q35146917) (← links)
- Low dose of acetylsalicylic acid and oxidative stress-mediated endothelial dysfunction in diabetes: a short-term evaluation (Q35218036) (← links)
- Intracellular Erythrocyte Platelet-activating Factor Acetylhydrolase I Inactivates Aspirin in Blood (Q35266471) (← links)
- Competitive enzymatic interactions determine the relative amounts of prostaglandins E2 and D2. (Q35429824) (← links)
- Activation of nuclear receptors by prostaglandins (Q35573256) (← links)
- Aspirin: pharmacology and clinical applications (Q35608778) (← links)
- Thromboxane A2 agonist modulation of excitatory synaptic transmission in the rat hippocampal slice (Q35874154) (← links)
- A simple and robust UPLC-SRM/MS method to quantify urinary eicosanoids (Q35897007) (← links)
- Platelet isoprostane overproduction in diabetic patients treated with aspirin (Q35976574) (← links)
- Platelets and metastasis revisited: a novel fatty link (Q35984309) (← links)
- Selective COX-2 inhibitors and risk of myocardial infarction (Q36173750) (← links)
- Antiplatelet and antithrombotic effects of cordycepin-enriched WIB-801CE from Cordyceps militaris ex vivo, in vivo, and in vitro (Q36215337) (← links)
- Coagulopathy in traumatic brain injury (Q36262718) (← links)
- Pharmacological basis of different targets for the treatment of atherosclerosis. (Q36346487) (← links)
- Non-steroid anti-inflammatory drugs, prostaglandins, and cancer (Q36689177) (← links)
- Aspirin hydrolysis in plasma is a variable function of butyrylcholinesterase and platelet-activating factor acetylhydrolase 1b2 (PAFAH1b2) (Q36796842) (← links)
- Total saponin from korean red ginseng inhibits thromboxane A2 production associated microsomal enzyme activity in platelets (Q36861022) (← links)
- A critical review of antiplatelet treatment in peripheral arterial disease. (Q36883643) (← links)
- Histamine directly and synergistically with lipopolysaccharide stimulates cyclooxygenase-2 expression and prostaglandin I(2) and E(2) production in human coronary artery endothelial cells (Q37003162) (← links)
- Method development and validation for ultra-high pressure liquid chromatography/tandem mass spectrometry determination of multiple prostanoids in biological samples (Q37044610) (← links)
- Inhibitory effects of epigallocatechin-3-gallate on microsomal cyclooxygenase-1 activity in platelets (Q37145480) (← links)
- Prostanoids in health and disease (Q37354582) (← links)
- Age-related increase of thromboxane B2 and risk of cardiovascular disease in atrial fibrillation (Q37457432) (← links)
- Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay (Q37596628) (← links)
- Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors (Q37738868) (← links)
- Platelet biology and implications for antiplatelet therapy in atherothrombotic disease (Q37766688) (← links)
- Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises (Q37827882) (← links)